In contrast, another study found no correlation of TGFα serum levels and clinical outcome in KRAS wild-type metastatic colorectal cancer patients treated with panitumumab or cetuximab (Takahashi et al. 2014). The gene discussed is KRAS; the disease is metastatic colorectal cancer.